Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    


Addressing Opioid Usage in the Hospital Setting


 

Recent Studies Look at Caldolor® as Effective Pain Management Option

Like any chronic condition, addiction becomes a lifelong battle once the disease process has begun. Also like many chronic conditions, there is a point where early intervention could potentially change disease trajectory and outcomes.

When it comes to opioid addiction and pain management, those upstream decisions often happen in the inpatient setting. Recently published literature draws a correlation between the use of Caldolor® (ibuprofen) Injection and a decreased need for opioids in certain patient populations. Two studies released this summer focused on Caldolor, a product of Nashville-based Cumberland Pharmaceuticals, as an adjunct to opioid analgesics in orthopaedic trauma patients and in managing postoperative pain.


Marty Cearnal

Marty Cearnal, executive vice president and chief commercial officer for Cumberland Pharmaceuticals, said a robust public health effort to reduce opioid use was in place prior to the pandemic. While the message might have moved to the back burner over the past few months, the need to address opioid addiction remains as critical as ever.

"We're doing everything that we can to aid in this effort to reduce opioid overuse," said Cearnal. "As with all drugs, there's an appropriate place and time for their use," he added of prescribing opioids.

However, he continued, "We believe that with drugs like Caldolor on the market, there is now a significant opportunity to reduce the use of opioids."

While opioids remain an effective rescue option in a breakthrough pain episode ... and chronic pain is outside of Caldolor's purview ... Cearnal said there are large numbers of hospitalized patients who could benefit from having an opioid alternative. He added physicians are increasingly looking at using combinations of approved drugs to replace opioids. "A new treatment strategy has emerged over the last several years," he noted. "Multimodal pain management uses a range of non-opioid drugs that act in different ways to manage a patient's pain."

Caldolor, which has FDA approval for use in adults and pediatric patients six months and older, is a nonsteroidal anti-inflammatory drug (NSAID). As such, it has the hallmark properties of this class of drugs to work as an analgesic, anti-inflammatory and antipyretic.

However, noted Cearnal, "It's unique among NSAIDs in that Caldolor not only works peripherally - where all NSAIDS work - but it also works centrally." Whereas most NSAIDs cannot cross the blood-brain barrier, Caldolor can. "It allows it to work on different receptors that have an impact on the perception of pain," he explained.

"What we've consistently seen across all double-blind studies is that using Caldolor as opposed to standard of care, usually opioids, you can reduce the use of opioids in a patient up to 58 percent ... and at the same time, get better pain control," Cearnal stated.

An Aug. 18 review of clinical studies led by Stephen Southworth, MD, MBA, FACS, an orthopaedic surgeon out of Mississippi who participates in the speaker's bureau for Cumberland Pharmaceuticals, bore out those findings. The article, published in the journal Clinical Therapeutics, reviewed 1,062 adult patients with 757 receiving Caldolor and 305 receiving placebo or a comparator medication.

The authors found when administered in rapid infusion (five to seven minutes) immediately prior to surgery, patients given Caldolor experienced less postoperative pain and decreased opioid use. For that reason, Southworth and colleagues said the drug should be considered as part of Enhanced Recovery After Surgery (ERAS) protocols with first dose administered immediately prior to surgery.

In addition to adopting a multimodal therapeutic strategy, Cearnal said setting realistic expectations for patients is another important key to reducing opioid use. "Zero pain, especially right after surgery, is probably an unrealistic goal," he pointed out. "If patients are willing to accept a low level of discomfort, then a lot of opioid use can be avoided ... and after a day or so, pain typically subsides greatly."

A number of research studies and scholarly articles support this assertion and find patients can and do power through some postoperative pain and tend to do so with more ease when preoperative discussions set expectations. "If you can get them through that first 24 to 48 hours without opioid use or significantly reduced opioid use, you have the best chance of reducing the risk of abuse and addiction," added Cearnal.

As part of Cumberland Pharmaceutical's campaign to increase awareness around multimodal options to reduce opioid misuse, Cearnal said they have created a series of continuing medical education programs on the Caldolor website, have provided speakers and one-on-one consultations to discuss effective pain management strategies and ERAS protocols, and are partnering with pharmacists.

"We're working with the Tennessee Pharmacists Association in the development of opioid reduction protocols," said Cearnal. "We've convened a meeting with some of the leading pharmacists in the association and are developing concepts of how to best deploy strategies around surgeries in Tennessee as a model."

Additionally, Cumberland Pharmaceuticals has developed a program in the state to make Caldolor available at no charge to rural hospitals as part of an evaluation protocol to reduce opioid use. Rural hospitals can reach out to the Tennessee Hospital Association or Tennessee Pharmacists Association for more information and parameters.

WEB:

Cumberland Pharmaceuticals

Caldolor

 
Share:

Related Articles:


Recent Articles

Ascension Saint Thomas Heart First in State, Region, Ascension to Offer Novel Medical Technique

On February 9, Ascension Saint Thomas Hospital West became the first Ascension hospital in the country and the only medical facility in Tennessee to offer intracoronary brachytherapy, a procedure that helps improve chest pain in patients with stents that have re-narrowed (sometimes called "collapsed") and reduces the chance of them narrowing again in the future.

Read More

Functional Seizures Associated with Stroke, Psychiatric Disorders in Electronic Health Records Study

In a large-scale study of electronic health records, Vanderbilt University Medical Center investigators have determined the prevalence of functional seizures and characterized comorbidities associated with them.

Read More

New survey shows minorities, children missing cancer screenings and vaccinations

52% of adults missing lifesaving screenings to prevent cancer are not rescheduling them

Read More

Sarah Cannon Cancer Institute at Swedish Medical Center Sheds New Light on Brain Tumors

Neurosurgery is a complex and intricate process, and it is important to continuously refine and seek innovative techniques to make it safer, gentler and more precise and effective.

Read More

Study Finds Recommended ICU Sedatives Equally Safe, Effective

Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.

Read More

Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer

Study to focus on using saliva in the analysis of cell-free circulating tumor DNA (ctDNA) to accurately and non-invasively detect non-small cell lung cancer (NSCLC).

Read More

DRUG COMPANIES URGED TO PROVIDE DISCOUNTS TO 340B COMMUNITY PHARMACIES

Yesterday, counsel for the American Hospital Association and the five other national groups and three individual hospital systems that sued the Department of Health and Human Services (HHS) over its failure to halt drug company actions that undermine the 340B drug pricing program sent letters demanding that the offending drug companies immediately halt their illegal activities.

Read More

Study Shows Drastic Increases in Opioid-Affected Births

The rate of mothers who had an opioid-related diagnosis when delivering their baby increased by 131% from 2010-2017, as the incidence of babies diagnosed with drug withdrawal, known as neonatal abstinence syndrome (NAS), increased by 82% nationally during that same time period.

Read More

Case Management: Enhancing Revenue, Care Transitions and Patient Outcomes throughout the Hospital System

The importance of hospital and health system case management has grown exponentially over the past 10 years and is now getting attention from leaders throughout the healthcare industry.

Read More

TennCare Block Grant Waiver Approved

More than a year after submitting Amendment 42 to the Centers for Medicare and Medicaid Services (CMS) requesting a waiver to increase flexibility in the administration of the state's Medicaid program, Tennessee has received an affirmative nod to move forward.

Read More

Email Print
 
 

 

 


Tags:
Addiction, Caldolor, Cumberland Pharmaceuticals, Marty Cearnal, Opioid Use, Pain Management  , Surgical Pain, Trauma Pain
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: